BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 27074084)

  • 1. Multiple Sclerosis and Antibodies against KIR4.1.
    Pröbstel AK; Kuhle J; Lecourt AC; Vock I; Sanderson NS; Kappos L; Derfuss T
    N Engl J Med; 2016 Apr; 374(15):1496-8. PubMed ID: 27074084
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of KIR4.1 as an Immune Target in Multiple Sclerosis.
    Chastre A; Hafler DA; O'Connor KC
    N Engl J Med; 2016 Apr; 374(15):1495-6. PubMed ID: 27074083
    [No Abstract]   [Full Text] [Related]  

  • 3. Lack of confirmation of anti-inward rectifying potassium channel 4.1 antibodies as reliable markers of multiple sclerosis.
    Nerrant E; Salsac C; Charif M; Ayrignac X; Carra-Dalliere C; Castelnovo G; Goulabchand R; Tisseyre J; Raoul C; Eliaou JF; Labauge P; Vincent T
    Mult Scler; 2014 Nov; 20(13):1699-703. PubMed ID: 24756568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low reliability of anti-KIR4.1
    Marino M; Frisullo G; Di Sante G; Samengo DM; Provenzano C; Mirabella M; Pani G; Ria F; Bartoccioni E
    Mult Scler; 2018 Jun; 24(7):910-918. PubMed ID: 28548026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibodies to the inward rectifying potassium channel 4.1 in multiple sclerosis: different methodologies--conflicting results?
    Hemmer B
    Mult Scler; 2015 Apr; 21(5):537-9. PubMed ID: 25583849
    [No Abstract]   [Full Text] [Related]  

  • 6. Increased anti-KIR4.1 antibodies in multiple sclerosis: could it be a marker of disease relapse?
    Brill L; Goldberg L; Karni A; Petrou P; Abramsky O; Ovadia H; Ben-Hur T; Karussis D; Vaknin-Dembinsky A
    Mult Scler; 2015 Apr; 21(5):572-9. PubMed ID: 25392324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potassium channel KIR4.1-specific antibodies in children with acquired demyelinating CNS disease.
    Kraus V; Srivastava R; Kalluri SR; Seidel U; Schuelke M; Schimmel M; Rostasy K; Leiz S; Hosie S; Grummel V; Hemmer B
    Neurology; 2014 Feb; 82(6):470-3. PubMed ID: 24415573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of potassium channel KIR4.1 antibodies in Multiple Sclerosis patients.
    Marnetto F; Valentino P; Caldano M; Bertolotto A
    J Immunol Methods; 2017 Jun; 445():53-58. PubMed ID: 28300540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibodies to potassium channels in multiple sclerosis.
    Cross AH; Waubant E
    N Engl J Med; 2012 Jul; 367(2):172-4. PubMed ID: 22784120
    [No Abstract]   [Full Text] [Related]  

  • 10. Disease mechanisms in MS: the potassium channel KIR4.1--a potential autoantigen in MS.
    Racke MK
    Nat Rev Neurol; 2012 Nov; 8(11):595-6. PubMed ID: 22986435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potassium channel KIR4.1 as an immune target in multiple sclerosis.
    Srivastava R; Aslam M; Kalluri SR; Schirmer L; Buck D; Tackenberg B; Rothhammer V; Chan A; Gold R; Berthele A; Bennett JL; Korn T; Hemmer B
    N Engl J Med; 2012 Jul; 367(2):115-23. PubMed ID: 22784115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-Kir4.1 Antibodies in Multiple Sclerosis: Specificity and Pathogenicity.
    Imamura M; Higuchi O; Maeda Y; Mukaino A; Ueda M; Matsuo H; Nakane S
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33348803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Humoral Responses to Diverse Autoimmune Disease-Associated Antigens in Multiple Sclerosis.
    Malyavantham K; Weinstock-Guttman B; Suresh L; Zivadinov R; Shanahan T; Badgett D; Ramanathan M
    PLoS One; 2015; 10(6):e0129503. PubMed ID: 26065913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimyelin antibodies in multiple sclerosis.
    Mantegazza R
    N Engl J Med; 2003 Dec; 349(23):2269-71; author reply 2269-71. PubMed ID: 14663868
    [No Abstract]   [Full Text] [Related]  

  • 15. Absence of antibodies against KIR4.1 in multiple sclerosis: A three-technique approach and systematic review.
    Navas-Madroñal M; Valero-Mut A; Martínez-Zapata MJ; Simón-Talero MJ; Figueroa S; Vidal-Fernández N; López-Góngora M; Escartín A; Querol L
    PLoS One; 2017; 12(4):e0175538. PubMed ID: 28414733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential loss of KIR4.1 immunoreactivity in multiple sclerosis lesions.
    Schirmer L; Srivastava R; Kalluri SR; Böttinger S; Herwerth M; Carassiti D; Srivastava B; Gempt J; Schlegel J; Kuhlmann T; Korn T; Reynolds R; Hemmer B
    Ann Neurol; 2014 Jun; 75(6):810-28. PubMed ID: 24777949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cloning, expression, and localization of a rat hepatocyte inwardly rectifying potassium channel.
    Hill CE; Briggs MM; Liu J; Magtanong L
    Am J Physiol Gastrointest Liver Physiol; 2002 Feb; 282(2):G233-40. PubMed ID: 11804844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced accumulation of Kir4.1 protein, but not mRNA, in a murine model of cuprizone-induced demyelination.
    Nakajima M; Kawamura T; Tokui R; Furuta K; Sugino M; Nakanishi M; Okuyama S; Furukawa Y
    Brain Res; 2013 Nov; 1537():340-9. PubMed ID: 24070676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers in multiple sclerosis: role of antibodies.
    Berger T; Reindl M
    Dis Markers; 2006; 22(4):207-12. PubMed ID: 17124342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Myelin oligodendrocyte glycoprotein (MOG) antibody and demyelination].
    Fukaura H
    Nihon Rinsho; 2010 Jun; 68 Suppl 6():637-40. PubMed ID: 20942151
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.